financetom
Business
financetom
/
Business
/
Abbvie to record $3.5 bln charge related to schizophrenia drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abbvie to record $3.5 bln charge related to schizophrenia drug
Jan 10, 2025 6:04 AM

Jan 10 (Reuters) - Abbvie ( ABBV ) said on Friday it

will record a charge of about $3.5 billion related to its

experimental schizophrenia drug, emraclidine, which recently

failed in two mid-stage studies.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved